Navegando por Palavras-chave "premenopause"
Agora exibindo 1 - 4 de 4
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosAnalysis of collagen in parametrium and vaginal apex of women with and without uterine prolapse(Springer, 2002-11-01) Takano, C. C.; Girao, MJBC; Sartori, MGF; Castro, R. A.; Arruda, R. M.; Simoes, M. J.; Baracat, E. C.; Lima, G. R. de; Universidade Federal de São Paulo (UNIFESP)Our objective was to compare the amount of collagen in parametrium and vaginal apex between women with uterine prolapse at pre- and postmenopause, and in women without prolapse. the study included 22 premenopausal women without prolapse (group A), 10 premenopausal women with prolapse (group 13), and 23 postmenopausal women with prolapse (group Q (total 55). Patients in group A underwent abdominal hysterectomy for uterine leiomyoma, and patients in groups B and C underwent vaginal hysterectomy. During the surgical procedure we obtained biopsies from the lateral parametrium and vaginal apex. the tissue was stained for histological analysis with picrosirius. We observed a lower amount of collagen in the parametrium of women with uterine prolapse, both in menacme and in postmenopause, than in the parametrium of women without prolapse. We observed no statistically significant difference in vaginal apex between the groups.
- ItemSomente MetadadadosEffect of a half dose of tamoxifen on proliferative activity in normal breast tissue(Elsevier B.V., 1999-10-01) Bernardes, JRM; Nonogaki, S.; Seixas, M. T.; Lima, G. R. de; Baracat, E. C.; Gebrim, L. H.; Universidade Federal de São Paulo (UNIFESP)Objectives: To investigate the proliferative activity of the mammary gland epithelium and plasma levels of progesterone, estradiol, prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and sex hormone-binding globulin (SHBG) in premenopausal women treated with 10 and 20 mg of tamoxifen (TAM) for 22 days. Patients and methods: A randomized double-blind study was performed with 43 premenopausal women with a diagnosis of fibroadenoma of the breast. the patients were divided into three groups: A (n = 15, placebo); B (n = 15, TAM 10 mg/day) and C (n = 13, TAM 20 mg/day). They started taking an oral dose of TAM or placebo on the very first day of the menstrual cycle. Lumpectomy was performed on the 22nd day of therapy. Normal breast tissue samples were collected during surgery, immediately immersed in 10% buffered formalin, processed for routine histology and immunohistochemistry for proliferating cell nuclear antigen (PCNA) detection. Two peripheral blood samples were collected, both on the 22nd day of the menstrual cycle, in order to evaluate the hormone levels. PCNA expressing epithelial cells were quantified by using a digital program Kontron Image System KS-300 in 1000 cells (400 x). Results: the percentage of cells expressing PCNA was significantly higher in the group receiving placebo (group A, 50.3%) when compared to groups receiving TAM 10 or 20 mg/day (group B, 24.1%; and group C, 23.2%, respectively) (P < 0.001). Differences between groups B and C were not significant. Levels of progesterone, estradiol and SHBG were significantly higher in B and C groups compared to group A. Increasing concentrations of FSH (P < 0.0045) and lower levels of prolactin (P < 0.0055) were only found in the group receiving 20 mg/day of TAM (group C). Conclusions: A 22-day TAM therapy, either with 10 or 20 mg/day, significantly reduced the PCNA expression and therefore the proliferative activity of the normal human breast tissue. Increasing levels of estradiol, progesterone and SHBG were associated with TAM therapy at 10 or 20 mg/day. However, a significant change of the level of FSH and prolactin was reached only with a 20-mg/day dose. (C) 1999 International Federation of Gynecology and Obstetrics.
- ItemSomente MetadadadosThe effect of tamoxifen on the proliferative activity of fibroadenomas(Elsevier B.V., 2002-05-01) Bernardes, JRM; Seixas, M. T.; Gebrim, L. H.; Universidade Federal de São Paulo (UNIFESP)
- ItemSomente MetadadadosEffects of tamoxifen on the breast in the luteal phase of the menstrual cycle(Elsevier B.V., 1998-07-01) Uehara, J.; Nazario, ACP; Lima, G. R. de; Simoes, M. J.; Juliano, Y.; Gebrim, L. H.; Universidade Federal de São Paulo (UNIFESP)Objectives: the effect of tamoxifen on cyclic mastalgia and on chemoprophylaxis against breast cancer is little known, mainly due to the difficulties in studying the normal human gland. We proposed to evaluate the mitotic index and the nuclear volume of the lobule of women medicated with tamoxifen only during the luteal phase of the menstrual cycle in order to observe the effect of tamoxifen on the normal human mammary gland. Methods: Twenty-four premenopausal women with fibroadenoma diagnosed via biopsy were studied. the phase of the cycle was determined by the date of menstruation and serum progesterone level in the luteal phase (greater than or equal to 3 ng/ml). the patients admitted to the study and were given written informed consent to participate in the investigation, which was previously approved of by the hospital Ethics Committee. Patients were divided at random into two groups: Group I consisted of 12 untreated women (control) and Group II consisted of 12 patients treated with 20 mg/day tamoxifen for 10 consecutive days beginning on the 13th day of the menstrual cycle. in both groups, the patients were submitted to biopsies of the nodule and of a 1-cm(3) fragment of adjacent mammary parenchyma between the 23rd and 26th day of the cycle. the mitotic index (number of mitoses/1000 nuclei counted) and mean nuclear volume (mean of 10 nuclear volumes for each case) were measured. Results: No mitosis was observed in Group II. There was a reduction in the mean nuclear volume in Group II (Mann-Whitney test). Conclusions: Tamoxifen, when administered only during the luteal phase of the menstrual cycle, significantly reduces the nuclear volume and mitotic activity of the epithelium. This data demonstrates an antagonistic action of tamoxifen on estrogen even when administered for short periods of time. (C) 1998 International Federation of Gynecology and Obstetrics.